Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BNB Plus ( (BNBX) ) has issued an update.
On January 15, 2026, BNB Plus Corp. announced that director Elizabeth M. Schmalz Shaheen resigned from the company’s board, effective immediately. The company stated that her departure did not stem from any disagreement regarding its operations, policies or practices, suggesting the change reflects a routine governance transition rather than signaling strategic or operational conflict for stakeholders.
Spark’s Take on BNBX Stock
According to Spark, TipRanks’ AI Analyst, BNBX is a Neutral.
Applied DNA Sciences faces substantial financial and operational challenges, as indicated by declining revenues and net losses. Despite some positive strategic moves, such as focusing on LineaRx, the stock suffers from poor technical indicators and valuation metrics. The company’s ongoing financial struggles and the uncertainties highlighted in the earnings call contribute to a low overall stock score.
To see Spark’s full report on BNBX stock, click here.
More about BNB Plus
Average Trading Volume: 157,131
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.85M
Find detailed analytics on BNBX stock on TipRanks’ Stock Analysis page.